GeneSearch is a small business owned by Paul and Sally Taylor, with office and lab facilities located in Bozeman, Montana. The Taylors, who were prominent llama breeders in the 80s and 90s, developed and taught the principles of embryo transfer in llamas and alpacas. They have produced more than 500 live llama and alpaca babies via embryo transfer, and have five significant scientific papers published in respected journals. The Taylors have an embryo transfer clinic (for work with llamas) and a well-equipped laboratory on their ranch adjoining wilderness land in southwest Montana.
After more than 10 years of research into the freezing of llama embryos, Paul invented a co-axial microtool for removal of water solution from the central space of these llama embryos. That procedure enabled him to freeze llama embryos successfully, to produce pregnancies and, eventually, the first two live babies from the frozen/thawed embryos of llamas in 2005 and 2006. The original tool was quite simple and at that time there was no indication that this new tool would have any significance beyond its application in freezing of llama embryos. After years of design and research, Paul’s simple micro tool has created a paradigm shift in embryo technology: The GeneSearch Embryo Cradle.
Paul and Sally Taylor, now both in their 70s, are preparing to sell the company and its patents. Their main goal in the continuing effort to develop and popularize the GeneSearch Embryo Cradle is to see the tool delivered into the hands of a reputable company or group of individuals who will continue the process of optimizing it and commercialize it for general use. They are not looking for investors, but rather for a business entity to take over responsibility for the future of the device. They would be happy to sell GeneSearch, Inc., with the intellectual property rights, or to license those rights on an exclusive basis. They will continue to fulfill their obligations in connection with the NIH grant projects in progress or pending, which will involve them for at least the next three years.